Vaxcyte Inc. filed SEC Form 8-K: Leadership Update
$PCVX
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 1, 2025
_____________________________________________
(Exact name of Registrant as Specified in Its Charter)
_____________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s Telephone Number, Including Area Code: (650 ) 837-0111
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed Dr. Olivier Brandicourt to the Board as a Class III director, which appointment became effective immediately. Dr. Brandicourt’s term will expire at the Company’s annual meeting of stockholders in 2026.
There are no arrangements or understandings between Dr. Brandicourt and any other persons pursuant to which he was selected as a director. The Board has determined that Dr. Brandicourt qualifies as an independent director under the independence requirements set forth under Rule 5605(a)(2) of the Nasdaq Rules and listing standards. Additionally, there are no transactions involving the Company and Dr. Brandicourt that the Company would be required to report pursuant to Item 404(a) of Regulation S-K.
In connection with his appointment to the Board and pursuant to the Company’s non-employee director compensation program as currently in effect (the “Director Compensation Program”), Dr. Brandicourt will receive an initial equity award of a nonstatutory stock option to purchase shares of the Company’s common stock with an equivalent value of $800,000 (the “Initial Grant”). The Initial Grant will vest over 36 months, 1/3 of which will vest on the anniversary date on which Dr. Brandicourt was appointed to the Board and 1/36 of which will vest monthly thereafter, subject to Dr. Brandicourt’s continuous service to the Company through each such date. The Initial Grant is subject to the terms and conditions of the Company’s 2020 Equity Incentive Plan and its related agreements.
Pursuant to the Director Compensation Program, Dr. Brandicourt will also receive an equity award on the date of each annual meeting of stockholders, which is currently comprised of an equity award with an equivalent value of $450,000, 75% of which shall be a nonstatutory stock option to purchase shares of the Company’s common stock (the “Annual Option Grant”) and 25% of which shall be restricted stock units (the “Annual RSU Grant” and together with the Annual Option Grant, the “Annual Grant”). The Annual Option Grant will vest monthly and fully vest on the earlier of the first anniversary of the grant date or the day prior to the next annual meeting of stockholders, and the Annual RSU Grant will fully vest on the earlier of the first anniversary of the grant date or the day prior to the next annual meeting of stockholders, subject to Dr. Brandicourt’s continuous service to the Company through each such date. The Annual Grant would become fully vested upon a change in control, subject to Dr. Brandicourt’s continuous service to the Company through such date.
In accordance with the Director Compensation Program, Dr. Brandicourt will also receive an annual cash retainer for his service as a Board member, which is currently set at $50,000 per year, with payment pro-rated for any partial period of service.
The Company has entered into its standard form of indemnification agreement with Dr. Brandicourt.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| VAXCYTE, INC. | |||||||||||
| Date: | May 1, 2025 | By: | /s/ Andrew Guggenhime | ||||||||
| Andrew Guggenhime President and Chief Financial Officer | |||||||||||